Argos Therapeutics

About:

Argos Therapeutics develops immunotherapy treatments for cancers, infectious and autoimmune diseases, and transplantation rejection.

Website: http://www.argostherapeutics.com

Twitter/X: argosthera

Top Investors: Horizon Technology Finance, Lumira Ventures, Silicon Valley Bank, Caisse de Depot et Placement du Quebec, Forbion Capital Partners

Description:

Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.